Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 22 Oct 2025
Inspired by tensions between health and financial well-being during the COVID-19 pandemic, a new model could significantly improve predictions of how disease will spread by acknowledging the trade-offs in a health crisis ...
Read Full News8 Pulmonology Headlines You Missed in Q3 2026
PROPEL will test imeroprubart, an investigational FcRn blocker, against placebo in adults with mild to severe generalized myasthenia gravis.
Here's some of what is coming soon to NeurologyLive® this week.
New analyses from the D1AMOND clinical program found that 69.8% of participants achieved a clinically meaningful reduction in tic severity within 8 weeks of ecopipam treatment, while an interim 18-month analysis showed sustained improvement without new safety signals.
Full results from the phase 2b LUMA showed that investigational BIIB122/DNL151 did not slow confirmed clinical worsening in early-stage Parkinson's disease compared with placebo.
Early phase 1 findings showed that the PROTAC LRRK2 degrader ARV-102 was associated with improvements in saccadic hypometria and changes in CSF markers of endolysosomal function, neuroinflammation, synaptic integrity, and axonal guidance in participants with Parkinson disease.
6 Nephrology Headlines You Missed in September 2026
1.
The New Perfectionism Problem in Medical Training
2.
How Low Does PSA Need to Go in Metastatic Prostate Cancer?
3.
Detecting invasive nodules could be key to preventing unnecessary pancreatic cancer surgery
4.
Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care
5.
Retifanlimab-Chemo Combo Boosts PFS in Advanced Squamous Cell Anal Cancer
1.
Progressive Updates in Oncology for Healthcare Excellence
2.
Precision Erythropoietic Modeling for Hematologic Disorders
3.
Unlocking the Potential of Reticulocytes: The Key to Enhanced Blood Production
4.
Molecular Matching for Precision Cancer Therapy
5.
Oncology Trials Roadmap: From Drug Discovery to Delivery and Patient Access
1.
International Conference on Cancer Nursing and Rehabilitation Strategies
2.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
3.
International Conference on Innovations in Critical Care for Oncology and Cardiology
4.
International Symposium on Oncology, Cardiology and Critical Care Innovations
5.
International Conference on Cancer Nursing and Hematology Support
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII
2.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
3.
Case-Based Learning: Oncology
4.
Current Scenario of Cancer- Q&A Session to Close the Gap Part II
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge